SCHEMBL4355695

SCHEMBL4355695

NNc1nc(N)nc2ccc(-c3cnn(Cc4ccccc4)c3)cc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.58
PIK3CA P42336 1/20 0.58
PIK3CB P42338 1/20 0.58
PI4KA P42356 1/20 0.58
PIK3CG P48736 1/20 0.58
PI4KB Q9UBF8 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.51
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
CREBBP Q92793 3/20 0.45
ALK Q9UM73 1/20 0.43
IKBKE Q14164 2/20 0.41
TBK1 Q9UHD2 2/20 0.41
NAMPT P43490 1/20 0.41
PGK1 P00558 1/20 0.41
DYRK1B Q9Y463 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
JAK1 P23458 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349571 0.84 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4354958 0.83 KDR (0.56) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4355875 0.83 PIK3CA (0.56) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4354947 0.82 PRMT5 (0.47) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4349718 0.81 PRMT5 (0.49) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4354962 0.79 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4358324 0.79 PIK3CA (0.42) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL4361887 0.79 PIK3CA (0.51) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL18041175 0.78 APP (0.46) TLR8TLR7APP
SCHEMBL4362189 0.78 DHFR (0.55) PIK3CAPI4KAPI4KBADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US claimed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US claimed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US claimed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US claimed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US claimed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 PIK3CD 4161/4885PIK3CA 3986/4885PIK3CB 4068/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 PIK3CD 4161/4885PIK3CA 3986/4885PIK3CB 4068/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 PIK3CD 4183/4885PIK3CA 4078/4885PIK3CB 4278/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 PIK3CD 3942/4885PIK3CA 3799/4885PIK3CB 4011/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 PIK3CD 3942/4885PIK3CA 3799/4885PIK3CB 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.